Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 352 results for "sun pharma advanced research"

Sun Pharma Advanced Research Q1 net loss narrows

SPARC reduces its net loss in Q1, gets Complete Response Lette...

Sun Pharma Advanced Research Company (SPARC), has managed to reduce its net loss to Rs. 1.65 crore during the first quarter ended June 2015 from Rs. 9.74 crore in the corresponding period of last year. Its net sales went up by 21.2 per cent to Rs. PharmaBiz, 1 month ago
Sensex rises 100 point despite China's wild movements The Financial Chronicle, 2 weeks ago
SPARC receives CRL from US FDA for Latanoprost NDA Financial Express, 1 month ago

14 images for sun pharma advanced research

India Infoline, 1 month ago
PR inside, 3 weeks ago
Sify, 1 month ago
SuperComputing, 1 day ago
DNA India, 6 days ago
Oneindia, 3 weeks ago
Satellite Spotlight, 1 month ago
Sify, 1 month ago
Sify, 1 month ago
New Indian Express, 1 month ago

Buy SPARC, Alembic, TV Today; sell Oil India: Mukadam

I Buy Sun Pharma Advanced Research Company (SPARC) with a target of Rs 440 and stoploss at Rs 400 Buy Alembic with a target of Rs 45 and stoploss at Rs 40 Buy TV Today Network with a target of Rs 202 and stoploss at Rs 186 Sell Oil India with a ...
 Moneycontrol.com1 month ago Bull's Eye: Buy Voltas, Rel Comm, OBC, sell Oil India  Money Control1 month ago Buy SPARC with a target of Rs 410: Prakash Gaba  Economic Times2 months ago

SPARC licenses Xelpros to Sun Pharmaceutical for US market, shares up 5%

At 9.55 am, share price of Sun Pharma Advanced Research Company was trading at Rs 426.50, up 5.01 per cent against its previous close.
 Money Today2 months ago Sensex, Nifty fall nearly 1%; Sun Pharma sheds over 15%  Hindu Business Line1 month ago Sun Pharma shares fall record 15% on profit warning  Livemint.com1 month ago SPARC Rallies 4% On Licensing Xelpros To Sun Pharma  One India2 months ago

Sell India Cement with a stop loss of 82, target of 70: Sandeep Wagle, Power My Wealth

'I would go with a sell in a India Cement with a stop loss of 82 and target of 70. A buy in a SPARC (Sun Pharma Advance Research) with a stop loss of 390 and target of 448.' In a chat with ET Now, Sandeep Wagle, Founder & CEO of Power My Wealth, shares his ...
 Economic Times2 months ago

Advanced Micro Devices Given Hold Rating at Canaccord Genuity (AMD)

Canaccord Genuity reissued their hold rating on shares of Advanced Micro Devices (NYSE:AMD) in a research report released on Wednesday morning, Analyst Ratings reports. Canaccord Genuity has also taken action a number of other stocks ...
 SleekMoney1 month ago

Sensex ends 100 pts up; Pharma stocks rally

Metal and realty stocks closed weak. Bank stocks too displayed some weakness, while FMCG, oil and power stocks closed on a mixed note. The BSE benchmark Sensex ended up 100.10 points or 0.36% at 27,931.64, after scaling a low of 27,721.25 and a ...
 Sify2 weeks ago Sensex up over 158 pts; Pharma, IT stocks trade firm  Sify2 weeks ago Market swings back, Sensex up 323 pts  New Delhi Pioneer1 month ago Sensex Ends on a Flat Note, Nifty Holds 8,600  NDTV Profit1 month ago

Retinitis Pigmentosa (Retinitis) Therapeutics Pipeline Review, H1 2015 - 24 Companies & 42 Drug Profiles

Research and Markets ( has announced the addition of the "Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive ...
 Individual.com1 month ago India Sterilizers and Surgical, Dental Care and Equipment Disinfectors Market 2015  AndhraNews.net1 month ago Research and Markets: Retinitis Pigmentosa (Retinitis) Therapeutics Pipeline Review, H1 2015 - 24 Companies & 42 Drug Profiles  Business Wire1 month ago RESEARCH AND MARKETS : Retinitis Pigmentosa (Retinitis) Therapeutics Pipeline Review, H1 2015 - 24 Companies & 42 Drug Profiles  4 Traders1 month ago
Money Today

Sun Pharma May File New Drug Application with USFDA: Shanghvi

HYDERABAD: India's largest drugmaker Sun Pharma may file application for a new drug with the US Food and Drug Administration in next two to three years, the company's Managing Director Dilip Shanghvi said today. The firm's research arm SPARC (Sun ...
 New Indian Express1 month ago Sun Pharma to file new drug application with USFDA: Report  Indian-Commodity1 month ago Sun Pharma plans to file new drug application with USFDA: Dilip Shanghvi  India Infoline1 month ago Sun Pharma falls 1% post USFDA audit of Maharashtra plant  Moneycontrol.com1 month ago
Business Today India

Indian pharma on road to new drug discovery

It is turning out to be a serious health scare. With bacteria fast developing resistance to existing antibiotics, we may soon reach a stage where a simple bruise may prove fatal. What is making things worse is that no new antibiotic has been ...
 Business Today India3 weeks ago Indian Pharmaceutical Company Soon to Register for a New Drug With USFDA  Med India1 month ago

Transport Corp, SPARC numbers on weekend

This weekend will see a host of companies declaring their financial performance for the April-June quarter. While Sun Pharma Advanced Research Co (SPARC), Fiem Industries, KS Oils, SREI Infra Finance, Seshasayee Paper, Transport Corporation of ...
 Hindu Business Line1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - sun pharma advanced research
Get updated on latest news & your favorite topics right in your inbox!
More     Less